Are you or a loved one currently facing bladder cancer? Stand Up To Cancer (SU2C) is supporting a clinical trial that may benefit patients with advanced or metastatic urothelial bladder cancer. This trial has the potential to make dramatic gains for future patient outcomes and survival of this disease.
Immunotherapies work by helping the patient’s immune system to help identify and fight cancer in the body. Currently, immunotherapies used to treat advanced bladder cancer are ineffective in approximately 75% of patients. This is because the immune system is controlled by “on” and “off” signals that tell the body when to attack and when to stand down. Cancer cells, however, can hijack this process, utilizing the “off” signal to stop the attack and effectively hide from the immune system.
What is epigenetic therapy?
Epigenetic therapy is the use of medicines to reprogram replicating cells to behave more like normal cells.
The goal of this trial is to help those patients whose cancers grow despite immunotherapy, by reversing their cancer’s resistance to immunotherapy (atezolizumab) by adding another type of treatment—epigenetic therapy (guadecitabine). The result, we believe, will be a one-two punch that is more effective than either approach has been on its own thus far.